NVTA - NVTA インビティ （）

An upcoming event has gene editing stocks rising today. Editas Medicine (NASDAQ: EDIT ) has announced plans to present some important trial data via a live webinar next week on June 12 at 8 a.m. Eastern, the clinical-stage genome editing company will present the clinical data from its RUBY trial of EDIT-301 as a treatment for severe sickle cell disease. In a statement released by the company, Editas also noted that it will present “initial clinical data from the EDITHAL trial of EDIT-301 for the treatment of transfusion-dependent beta thalassemia.” News of this event has kept EDIT stock in the green all day, indicating that the market is reacting well. Does this mean that this positive momentum will continue as the webinar date draws closer? Let’s take a closer look at the event and assess what investors should be expecting. What’s Happening With Gene Editing Stocks Editas isn’t the only company benefitting from this announcement. Several other gene editing stocks are on the rise, one of which is outperforming EDIT.

SAN FRANCISCO, May 31, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight, president and chief executive officer, will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023, at 12:40 p.m….

Invitae (NVTA) notifies that Chief Financial Officer Yafei (Roxi) Wen is resigning to pursue other opportunities, effective June 30, 2023. A search for successor is underway. Ms

In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index

Invitae (NVTA) said it will appeal a verdict in a patent case in a federal court in Delaware that found in favor of Natera (NTRA). Read more here.

SAN FRANCISCO, April 26, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30…

Ark Innovation CEO Cathie Wood said the stock is undervalued.

Futures Slide In Risk-Off End To Volatile Week US equity futures extended their recent weakness and traded near the week''s lows in early Friday trading as investors digested the latest corporate updates. Investors now await PMI data later today for further direction on the path for monetary policy. Contracts on the S&P 500 and the Nasdaq 100 drifted -0.2% lower as of 7:15 a.m. ET, as both indexes were set to end the week in negative territory, the Nasdaq underperforming slightly. Treasury yields edged higher, while the dollar advanced against other major currencies with a measure of its strength set for its first weekly gain in six weeks. Iron ore, gold and oil all decline, as the gains from the latest OPEC+ output cut are now all gone: so will OPEC cut again to reverse the slide in the one asset class that unlike stocks, everyone loves to short as a hedge for the coming recession? In premarket trading, Tesla edged higher after the electric-vehicle maker increased prices of its Model S and X vehicles in the United States just two days after cutting prices.

U.S. stock futures traded mixed this morning. Here are some big stocks recording gained in today’s pre-market trading session. Mullen Automotive, Inc. (NASDAQ: MULN ) shares jumped 30.2% to $0.1103 in pre-market trading after dropping around 6% on Thursday. ContextLogic Inc. (NASDAQ: WISH ) gained 21% to $8.69 in pre-market trading after the company announced a $50 million buyback program. Atai Life Sciences N.V. (NASDAQ: ATAI ) gained 8.6% to $2.38 in pre-market trading after gaining around 7% on Thursday. Invitae Corporation (NYSE: … Full story available on Benzinga.com

Invitae Corp (NYSE: NVTA ) shares are taking off … Full story available on Benzinga.com

The partnership will harness genetic and clinical data from millions of patients tested at Invitae and Deerfield''s expertise in drug discovery to address high unmet needs among rare disease patients SAN FRANCISCO, March 22, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical…

Genetics company Invitae (NVTA) said it is collaborating with healthcare software company Epic to streamline genetic testing

Invitae (NYSE: NVTA), a leading medical genetics company, today announced its partnership with Epic, an industry-leading healthcare software company. Through Aura, Epic''s specialty diagnostics suite, Invitae will streamline interactions with provider organizations in the Epic community, making test result information available in providers'' usual workflows so that it''s easier to use genetic insights to inform treatment decisions. "Genetic testing can inform some of the most important care decisions in patients'' lives, and Invitae is making it more accessible to both patients and providers across the Epic community," said Dave Fuhrmann, senior vice president of research and development at Epic. "Aura will help them do so by further enabling precision medicine at many of the nation''s leading healthcare organizations." "Our use of Aura allows patients and providers to seamlessly access genetic testing that can help identify at-risk individuals, enhance early detection and better

Invitae Corporation (NVTA)’s stock has witnessed a price hike of 2.60% from the previous close with its current price standing at $1.45. Its current price is -84.24% under its 52-week high of $9.18 and 6.37% more than its 52-week low of $1.36. Based on the past 30-day period, the stock price is -39.32% below the […]